CareValidate has unveiled CareGLP, a groundbreaking program aiming to transform the landscape of weight loss healthcare. By integrating their cutting-edge case management platform with a network of trusted suppliers, CareGLP provides businesses unprecedented access to GLP-1 therapies such as semaglutide and tirzepatide. This initiative opens up opportunities for health, wellness, fitness, and nutrition companies to merge GLP-1 medications into their offerings, thereby tapping into the rapidly expanding obesity care market.
The program offers a comprehensive and certified platform covering various aspects of obesity care, from diagnostics and assessment tools to medication management and access to specialised providers.
The launch of CareGLP comes at a strategic time, with JP Morgan predicting a significant surge in GLP-1 users. The forecast suggests around 15 million obese patients will be on GLP-1s by the end of the decade, and the number of GLP-1 users in the U.S. may reach 30 million by 2030, constituting approximately 9% of the population. CareGLP aims to cater to this growing demand by providing businesses with the tools to offer high-quality obesity care services.
CareGLP's innovative obesity telehealth solution emphasises inclusivity, allowing partnering brands to extend these services to customers regardless of their insurance status. The program is designed to meet individuals where they are in their chronic disease management journey, empowering businesses to run successful weight loss programs.
Click here to read the original news story.